Delivering non-viral genes for tissue regeneration with an improved hydrogel scaffold

Value Proposition

The safety concerns surrounding the use of viral vectors for gene delivery have led to the development and interest in non-viral gene delivery methods used to induce expression of a therapeutic transgene. Non-viral gene delivery methods are currently limited by the efficiency and duration of transfection. One approach to overcome these limitations the delivery of plasmids via injectable hydrogels that provide a localized, sustained transfection to nearby or infiltrating cells at the implantation site. However, the current injectable hydrogel delivery methods suffer from aggregation and an uneven distribution of DNA materials containing the desired genes, limiting therapeutic efficacy.


The inventors have developed an improved injectable hydrogel based on the microporous annealed particle (MAP) technology. This is a shredded form of the MAP hydrogel and utilizes different reagents to increase DNA polyplex concentration, homogenous DNA polyplex distribution and reduced hydrogel aggregation. The technology results in enhanced transfection efficiency and transgene expression that will subsequently improve tissue repair in vivo.

Other Applications

  • Providing structural support for cells and new tissue growth
  • Localalized delivery of therapeutic genes to infiltrating cells for regenerative medicine applications such as in wound healing, stroke recovery, or cartilage and bone regeneration


  • Improved cellular adhesion and infiltration compared to traditional MAP technology
  • Increased DNA polyplex loading into the hydrogel
  • Homogenous distribution of polyplex and reduced polyplex aggregation
  • Enhanced transfection efficiency and transgene expression
  • This technology can be applied to any hydrogel scaffold